| | By Kevin Dunleavy 2023 was all about diabetes and obesity drug sellers Novo Nordisk and Eli Lilly posting huge revenue gains as they were the only companies in the biopharma industry with double-digit gains. At the other end of the spectrum, sellers of COVID products saw dramatic decreases in revenue as Pfizer, the top revenue drugmaker in 2022, had a 41% decrease, while Moderna and BioNTech tumbled out of the top 20. |
|
|
|
By Gabrielle Masson In the same week that Genentech confirmed it's cutting 3% of its staff, the Roche subsidiary has terminated a cell therapy partnership with Adaptimmune Therapeutics worth up to $3 billion. |
By Max Bayer Pfizer's 2023 cost-cutting wave swept up a specific R&D team that worked closely with academics to swiftly develop new medicines. A company spokesperson confirmed that Pfizer has closed labs associated with the Centers for Therapeutic Innovation. |
By Andrea Park After Lady Gaga shared her latest commercial for Pfizer’s migraine medication Nurtec ODT on Instagram earlier this week, many of her fans flocked to the comments section to criticize her partnership with the Big Pharma. But they’re not the only ones who have a bone to pick with the superstar. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now! 
|
|
By Nick Paul Taylor AstraZeneca is sounding the crisis klaxon after spotting an “urgent and growing” global health situation that has “profound economic and environmental implications.” The drugmaker made the comments in response to forecasts of the impact of chronic kidney disease through 2032. |
By Max Bayer Regeneron is joining its pharma peers, launching its own venture capital wing. The New York pharma plans to commit $100 million annually for the first five years. |
By Conor Hale The preliminary first-quarter earnings report is a dour departure from the high notes heard earlier this year after PacBio posted 56% annual growth following two new platform launches. |
By Conor Hale After setting up more than $30 billion in medtech M&A spending within less than two years, Johnson & Johnson CEO Joaquin Duato said that trajectory will continue as the company looks to latch on to long-term growth. |
By Kevin Dunleavy In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. Now, two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA). |
By Fraiser Kansteiner In a docket entry dated Friday, Massachusetts federal judge Richard G. Stearns granted a stay on Moderna's COVID-19 vaccine patent infringement lawsuit against Pfizer and BioNTech. The move will give the Patent Trial and Appeal Board more time to review challenges against two of the three relevant patents in the litigation. |
By Zoey Becker The filling department closure comes as part of a regulatory commitment, a spokesperson said. The site in Kankakee County, Illinois, has been active for 70 years and employs around 1,500 workers. |
By Helen Floersh SelSym's "biomaterials approach" to developing synthetic platelets appears to have paid off so far, with successful results in mice, rats and pigs. The preclinical studies will likely be part of an investigational new drug application with the FDA. |
Fierce podcasts Don’t miss an episode |
| Using data from Fierce Biotech's layoff tracker, Gabrielle Masson and Max Bayer analyze the trends of layoffs in the first quarter of 2024, comparing them to previous years. |
|
|---|
|
|
|
Tuesday, April 23, 2024 | 11am ET / 8am PT Exceptions Management focuses on identifying and resolving issues arising during pharmaceutical product manufacturing and distribution. It is critical in the pharmaceutical sector due to patient safety and regulatory compliance and to avoid supply chain delays and product quarantine. Register now to learn more. 
|
|
Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today! Sponsored by: Sengenics Corporation LLC |
Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
eBook Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain. Download this eBook to learn more about the future state of health care dynamics and its affects along the pharmaceutical value chain. Presented by Optum Life Sciences and Advisory Board |
Executive Summary Learn about the current state of biopharma logistics with insights from 150 manufacturers in this exclusive market survey report. Download the report to learn about how regulatory factors and emerging therapies are having an effect on logistics. Sponsored by: Cardinal Health 3PL Services |
eBook Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes Sponsored by: Thermo Fisher Scientific |
Whitepaper Clinical trials demand accurate lab data. Central labs uphold standards by ensuring consistency in methodologies, equipment, and reporting. Robust and integrated analytical platforms can support this via real-time access to study and lab data with transparent reporting capabilities, as well as to facilitate critical clinical decision-making and solve drug developers' challenges. Learn more about Preclarus®️ Lab Solutions by PPD®️ from expert Chris Clendening in this paper. Sponsored by: PPD®️ Laboratory Services |
Whitepaper This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future. Sponsored by: PPD®️ Laboratory Services |
Whitepaper Selecting a 3PL with a proven track record of delivering high-quality services is critical to a successful pharma supply chain. Here's how. Sponsored by: BioCare |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
